ClinicalTrials.gg
Active, not recruitingNCT05619302Updated Jul 6, 2026

Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis

A Phase 3 interventional study of [68Ga]CBP8 PET/MRI in Cardiac Amyloidosis, sponsored by Brigham and Women's Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Brigham and Women's Hospital · Phase 3, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Amyloid Neuropathies, Familial with a site in United States — 23 open to participants now, 26 under way, 4 of them phase 3. Amyloid Neuropathies, Familial · United States.

Enrollment
30th of 38
18 · median 53
Started
2023
with 5 others
Phase 3
14 of 58
2 open now
Primary completion
2026-12
later than 3 of 25 live
Registered
37th of 58
by date
Lead sponsor
6 of 58
Brigham and Women's Hospital

Among the 58 studies in Amyloid Neuropathies, Familial with a site in United States, this one is the 30th largest by enrollment of the 38 interventional ones that give a count, is one of 6 that started in 2023, is one of 14 in phase 3, reaches primary completion later than 3 of the 25 other live ones, and was the 37th registered.

Amyloid Neuropathies, Familial

188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.

Browse Amyloid Neuropathies, Familial studies →

Open to participants now

23 of the 58 studies in Amyloid Neuropathies, Familial with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Amyloid Neuropathies, Familial with a site in United States, or all of them as a file.
02

Study summary

The primary aim of our pilot study is to determine whether fibrosis in the heart can be measured with [68Ga]CBP8, a positron emission tomography (PET) probe, using PET/magnetic resonance imaging (MRI) imaging, in 30 individuals with documented cardiac amyloidosis. The investigators will also enroll 15 individuals with recent myocardial infarction and 15 individuals with hypertrophic cardiomyopathy as positive controls for fibrosis, and the investigators will enroll 5 individuals without cardiovascular disease to undergo [68Ga]CBP8 PET/MRI imaging as a healthy control group.

The primary hypothesis of this study is that [68Ga]CBP8 will bind to interstitial collagen and quantify myocardial fibrosis in patients with cardiac amyloidosis. The investigators hypothesize that [68Ga]CBP8 uptake will be greater in patients with cardiac amyloidosis, myocardial fibrosis, and hypertrophic cardiomyopathy than in healthy controls. Secondly, the investigators also hypothesize that [68Ga]CBP8 activity more strongly correlates with standard MRI measures in patients with recent myocardial infarction and hypertrophic cardiomyopathy (where extracellular expansion is caused by myocardial fibrosis/collagen deposition) than in patients with cardiac amyloidosis (where myocardial fibrosis is combined with infiltration).

Read the detailed description

[68Ga]CBP8 is a novel gallium-68 labeled positron emission tomography (PET) probe that selectively binds collagen type I, which constitutes the majority of fibrotic tissue. In pre-clinical mouse models, [68Ga]CBP8 had the sensitivity to detect pulmonary fibrosis even at early stages and specificity for collagen uptake with low non-specific uptake in background tissues and organs. In preliminary studies in humans with idiopathic pulmonary fibrosis, patients tolerated [68Ga]CBP8 without adverse effects, and there was a strong correspondence between high collagen tracer signal and fibrotic lung regions established by chest computed tomography (CT) scan. [68Ga]CBP8 may be a valuable tool to detect and quantify collagen in the heart. The investigators propose to test [68Ga]CBP8 in a pilot study to image myocardial fibrosis in patients with cardiac amyloidosis.

Cardiac amyloidosis is characterized by myocardial interstitial infiltration by misfolded amyloid fibrils. Infiltration leads to increased myocardial stiffness and heart failure. In patients with cardiac amyloidosis, myocardial stiffness may also be caused by extracellular collagen deposition in the myocardium. Collagen deposition (i.e. myocardial fibrosis) results in adverse cardiac remodeling through similar mechanisms as amyloidosis and may potentiate heart failure in patients with cardiac amyloidosis. Myocardial fibrosis can be mitigated or prevented. In addition, therapies directed against amyloid fibrils also have differential response rates in cardiac amyloidosis patients with or without coexistent fibrosis. Magnetic resonance imaging (MRI) is an established method of measuring extracellular volume (ECV), a reliable way of quantifying myocardial fibrosis in conditions where the primary reason for ECV expansion is myocardial fibrosis. ECV may not be an optimal surrogate of myocardial fibrosis in patients with cardiac amyloidosis, where ECV is already quite expanded due to myocardial amyloid infiltration. Thus, a means of accurate, non-invasive quantitation of myocardial fibrosis has the potential to significantly improve cardiac amyloidosis care.

This pilot study is designed to understand whether myocardial fibrosis can be measured using a collagen 1 targeted radiotracer ([68Ga]CBP8). The investigators would like to study 15 patients with light-chain (AL) cardiac amyloidosis and 15 patients with transthyretin (ATTR) cardiac amyloidosis to understand differences in radiotracer uptake, if any. The investigators will also enroll 15 patients with recent myocardial infarction and 15 patients with hypertrophic cardiomyopathy as positive controls for fibrosis and will enroll 5 individuals without cardiovascular disease as negative controls.

The aim of this proposed research study is, using simultaneous PET/MRI imaging, to determine whether [68Ga]CBP8 uptake will accurately identify and quantify myocardial fibrosis in patients with cardiac amyloidosis, recent myocardial infarction, and hypertrophic cardiomyopathy. The aim of this study is also to correlate [68Ga]CBP8 PET uptake with standard MRI measures in patients with cardiac amyloidosis.

03

Conditions studied

  • Cardiac Amyloidosis

Keywords

  • Amyloidosis
  • Cardiac
  • Heart
  • Imaging
  • Diagnosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for AL-amyloid subjects:

  • Age > 18 years
  • Willing and able to provide consent
  • AL-CA: Diagnosis of systemic light chain amyloidosis by standard criteria: Immunofixation of serum, serum free light chain (FLC) assay, a of fat pad/bone marrow, or organ biopsy, followed by typing of the light chain using immunohistochemistry or immunogold assay with confirmation by mass spectroscopy as needed AND

    • Proof of cardiac involvement by AL amyloidosis
    • Abnormal cardiac biomarkers: abnormal high sensitivity TnT 5th generation levels (> 15 ng/L) or abnormal age-appropriate NT-proBNP (abnormal values: \< 50 years: > 450 pg/ml; 50-75 years: > 900 pg/ml; > 75 years: > 1800 pg/ml) OR
    • Abnormal echocardiogram (wall thickness > 12 mm in the absence of other causes of increased LV wall thickness) OR
    • Abnormal CMR (wall thickness > 12 mm, extracellular volume > 0.40 or typical CMR appearance of cardiac amyloidosis with difficulty nulling images and non-coronary distribution late gadolinium enhancement) OR
    • Positive endomyocardial biopsy

Inclusion Criteria for ATTR-amyloid subjects:

  • Age > 18 years
  • Willing and able to provide consent
  • ATTR-CA: Diagnosis of either wildtype or hereditary transthyretin cardiac amyloidosis by standard criteria: Endomyocardial biopsy followed by typing of the transthyretin amyloidosis using immunohistochemistry or immunogold assay with confirmation by mass spectroscopy as needed

    • Extracardiac biopsy with typical cardiac imaging findings
    • Hereditary ATTR amyloidosis by genetic testing OR
    • Grade 2 or grade 3 myocardial uptake of 99mTc-PYP if AL amyloidosis is excluded

Inclusion Criteria for recent myocardial infarction subjects:

  • Age > 18 years
  • Willing and able to provide consent
  • Recent MI: Diagnosis of recent type 1 myocardial infarction by standard criteria

    • More than 6 weeks from diagnosis of MI but within 6 months
    • Imaging evidence of loss of viable myocardium or persistent regional wall motion abnormalities in a pattern consistent with an ischemic etiology in more than one segment

Inclusion Criteria for hypertrophic cardiomyopathy subjects:

  • Age > 18 years
  • Willing and able to provide consent
  • Hypertrophic cardiomyopathy: Diagnosis of hypertrophic cardiomyopathy by standard criteria
  • MRI evidence of late gadolinium enhancement

Inclusion Criteria for recent healthy control subjects:

  • Age > 18 years
  • Willing and able to provide consent
  • No known cardiac amyloidosis or recent myocardial infarction

Exclusion Criteria:

  • Dialysis
  • (New York Heart Association) Class IV
  • Acute myocardial infarction within 6 weeks
  • Pregnancy or nursing
  • History of adverse events from or allergy to gadolinium contrast media
  • Hemodynamic instability
  • Severe claustrophobia despite use of sedatives
  • Decompensated heart failure (unable to lie flat for 1 hour)
  • Concomitant non-ischemic non-amyloid heart disease (valvular heart disease or dilated cardiomyopathy)
  • Body weight over limit for MRI table (>300 lbs)
  • for MRI (including non-compatible cardiac implantable electronic devices, drug infusion pumps, and metallic or electric implants)
  • Any other reason determined by the investigator to be unsuitable for the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    [68Ga]CBP8 PET/MRI Amyloid Subjects

    Individuals with documented cardiac amyloidosis will undergo \[68Ga\]CBP8 PET/MRI.

    Drug: [68Ga]CBP8 PET/MRI

  • Active comparator
    [68Ga]CBP8 PET/MRI Recent Myocardial Infarction Subjects

    Individuals with recent myocardial infarction will undergo \[68Ga\]CBP8 PET/MRI.

    Drug: [68Ga]CBP8 PET/MRI

  • Placebo comparator
    [68Ga]CBP8 PET/MRI Healthy Controls

    Individuals without documented cardiovascular disease will undergo \[68Ga\]CBP8 PET/MRI.

    Drug: [68Ga]CBP8 PET/MRI

  • Active comparator
    [68Ga]CBP8 PET/MRI Hypertrophic Cardiomyopathy Subjects

    Individuals with hypertrophic cardiomyopathy will undergo \[68Ga\]CBP8 PET/MRI.

    Drug: [68Ga]CBP8 PET/MRI

Interventions

  • Drug[68Ga]CBP8 PET/MRI

    Simultaneous cardiac PET/MRI images will be obtained following injection of \[68Ga\]CBP8

    Also known as: No other names

06

What researchers measure

Primary outcomes

  1. Mean Standardized Uptake Value (SUVmean) of [68Ga]CBP8 uptake in the heart

    Standardized uptake value (SUV) mean is defined as the mean \[68Ga\]CBP8 concentration measured within the left ventricular myocardium multiplied by the decay-corrected amount of injected \[68Ga\]CBP8 normalized to patient weight. We expect SUVmean will be greater in patients with cardiac amyloidosis and myocardial infarction compared with healthy control subjects.

    Time frame: 1 day

  2. Extracellular volume from clinically performed simultaneous cardiac MRI

    We will correlate \[68Ga\]CBP8 uptake with standard MRI extracellular volume (ECV) measures. We expect \[68Ga\]CBP8 activity to more strongly correlate with MRI in patients with myocardial infarction than cardiac amyloidosis.

    Time frame: 1 day

07

Study locations

1 site
08

References and documents

Publications

  • Montesi SB, Izquierdo-Garcia D, Desogere P, Abston E, Liang LL, Digumarthy S, Seethamraju R, Lanuti M, Caravan P, Catana C. Type I Collagen-targeted Positron Emission Tomography Imaging in Idiopathic Pulmonary Fibrosis: First-in-Human Studies. Am J Respir Crit Care Med. 2019 Jul 15;200(2):258-261. doi: 10.1164/rccm.201903-0503LE. No abstract available. PubMed 31161770 ↗
  • Desogere P, Tapias LF, Rietz TA, Rotile N, Blasi F, Day H, Elliott J, Fuchs BC, Lanuti M, Caravan P. Optimization of a Collagen-Targeted PET Probe for Molecular Imaging of Pulmonary Fibrosis. J Nucl Med. 2017 Dec;58(12):1991-1996. doi: 10.2967/jnumed.117.193532. Epub 2017 Jun 13. PubMed 28611243 ↗
  • Desogere P, Tapias LF, Hariri LP, Rotile NJ, Rietz TA, Probst CK, Blasi F, Day H, Mino-Kenudson M, Weinreb P, Violette SM, Fuchs BC, Tager AM, Lanuti M, Caravan P. Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Sci Transl Med. 2017 Apr 5;9(384):eaaf4696. doi: 10.1126/scitranslmed.aaf4696. PubMed 28381537 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Dec 2026, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2022
First posted
Nov 16, 2022
StartActual
Jan 3, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05619302
Responsible party
Sharmila Dorbala (Director of Nuclear Cardiology, Brigham and Women's Hospital) — Principal investigator
First posted
Nov 16, 2022
Start date
Jan 3, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 6, 2026

Study contacts

Sharmila Dorbala, MD
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion